# US 2009/0291933 A1 · Solid state forms of a pharmaceutical

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0291933 A1
- Document ID: US20090291933A1
- Status: Published application
- Kind: A1
- Application number: 12/418,559
- Filed: 2009-04-03
- Published: 2009-11-26
- Earliest claimed: 2008-04-03
- Assignees: Hollis-Eden Pharmaceuticals, Inc.
- Inventors: Steven K. White; Igor Ivanisevic; Kyle Stephens; Mark Andres; Brenton Skylar Wolfe
- Web page: https://patentgrep.com/patent/US20090291933A1

## CPC

- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07J 5/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, {i.e. only one oxygen bound to position 21 by a single bond}
- C07J 7/0005: {not substituted in position 21}
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include Form I anhydrate and Form IV and Form V solvates. The invention further relates to solid and suspension formulations containing 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in a described solid state form and use of the formulations to treat hyperglycemic conditions, such as type 2 diabetes and metabolic syndrome, and autoimmune conditions, such as rheumatoid arthritis, ulcerative colitis and type 1 diabetes, among other inflammation related conditions in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol and uses of such formulations in treating the described conditions.

## Claims

### Claim 1

Crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol.

### Claim 2 (depends on 1)

The crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol of claim 1 substantially free of amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol.

### Claim 3 (depends on 2)

The crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol of claim 2 wherein the crystalline form of 17α-ethynylandrost-5-ene-3β,7β,17β-triol is an anhydrate.

### Claim 4 (depends on 3)

The crystalline anhydrate of claim 3 wherein the anhydrate is Form I 17α-ethynylandrost-5-ene-3β,7β,17β-triol having (i) an X-ray powder diffraction pattern with peak positions of 10.38±0.1, 16.20±0.1 and 17.75±0.1 degrees 2-theta, optionally with one, two or three peak positions selected from the group consisting of 12.64±0.1, 15.08±0.1, 16.73±0.1, 28.92±0.1 degrees 2-theta, (ii) a differential scanning calorimetry thermogram with a sharp endotherm at about 266° C., obtained using a temperature ramp of 10° C./min, or (iii) the characteristics of (i) and (ii).

### Claim 5 (depends on 4)

The crystalline anhydrate of claim 4 wherein the Form I 17α-ethynylandrost-5-ene-3β,7β,17β-triol has (i) a Raman spectroscopy spectrum with absorptions at peak positions of about 2106 and 1674 cm−1, optionally with one, two or three absorptions with peak positions selected from the group consisting of 2947, 2887, 976, 507, 484, 470, 370, 301, 247 and 226 cm−1 or a Raman spectrum substantially identical to that of FIG. 5A or FIG. 5B, (ii) a morphology essentially as shown in FIG. 6A or FIG. 6B, or (iii) the characteristics of (i) and (ii).

### Claim 6 (depends on 3)

The crystalline anhydrate of claim 3 wherein the anhydrate is Form II 17α-ethynylandrost-5-ene-3β,7β,17β-triol having (i) an X-ray powder diffraction pattern with peak positions of 2.49±0.1, 5.04±0.1 and 16.20±0.1 degrees 2-theta, optionally with one, two or three peak positions selected from the group consisting of 7.46±0.1, 10.44±0.1, 17.73±0.1, 28.92±0.1 degrees 2-theta, (ii) a differential scanning calorimetry thermogram with a sharp endotherm at about 259° C. obtained using a temperature ramp of 10° C./min, or (iii) the characteristics of (i) and (ii).

### Claim 7 (depends on 2)

The crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol of claim 2 wherein the crystalline form of 17α-ethynylandrost-5-ene-3β,7β,17β-triol is a solvate.

### Claim 8 (depends on 7)

The solvate of claim 7 wherein the solvate is Form III 17α-ethynylandrost-5-ene-3β,7β,17β-triol having (i) an X-ray powder diffraction pattern with peak positions of 15.24±0.1, 15.66±0.1, 16.59±0.1 degrees 2-theta, optionally with one, two or three peak positions selected from the group consisting of 8.34±0.1, 12.27±0.1 and 27.75±0.1 degrees 2-theta, (ii) a differential scanning calorimetry thermogram with a broad endotherm centered at between about 105-108° C. obtained using a temperature ramp of 10° C./min, (iii) a thermogravimetric analysis thermogram with between about 8-9.6% weight loss from 20° C. to 100° C. using a temperature ramp of 10° C./min, or (iv) the characteristics of (i) and (ii) or (i) and (iii).

### Claim 9 (depends on 8)

The solvate of claim 8 wherein the Form III 17α-ethynylandrost-5-ene-3β,7β,17β-triol has a Raman spectroscopy spectrum with absorptions at peak positions of about 2108 and 1666 cm−1, optionally with one, two or three absorptions with peak positions selected from the group consisting of 2950, 2933, 1469, 983, 681, 654, 517, 380, 251 and 224 cm−1 or a Raman spectrum substantially identical to that of FIG. 13A or FIG. 13B.

### Claim 10 (depends on 8)

The solvate of claim 8 wherein the solvate is Form IV 17α-ethynylandrost-5-ene-3β,7β,17β-triol having (i) an X-ray powder diffraction pattern with peak positions of 15.24±0.1, 15.66±0.1, 16.62±0.1 degrees 2-theta, optionally with one, two or three peak positions selected from the group consisting of 8.31±0.1, 10.44±0.1, 12.27±0.1, 16.20±0.1 and 27.75±0.1 degrees 2-theta, (ii) a differential scanning calorimetry thermogram with a broad endotherm centered at between about 105-108° C. obtained using a temperature ramp of 10° C./min, (iii) a thermogravimetric analysis thermogram with between about 9-9.7% weight loss from 20° C. to 100° C. using a temperature ramp of 10° C./min, or (iv) the characteristics of (i) and (ii), (i) and (iii) or (i), (ii) and (iii).

### Claim 11 (depends on 10)

The solvate of claim 10 wherein the Form IV 17α-ethynylandrost-5-ene-3β,7β,17β-triol has a Raman spectroscopy spectrum with absorptions at peak positions of about 2108 and 1666 cm−1, optionally with one, two or three absorptions with peak positions selected from the group consisting of 2950, 2933, 1469, 983, 681, 654, 577, 467, 380, 251 and 224 cm−1 or a Raman spectrum substantially identical to that of FIG. 16A or FIG. 16B.

### Claim 12

Amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol substantially free of crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol.

### Claim 13 (depends on 12)

The amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol of claim 12 having (i) an X-ray powder diffraction pattern with a broad band centered at about 16 degree 2 theta or an X-ray powder diffraction pattern substantially identical to FIG. 20, (ii) a modulated differential thermal analysis thermogram with Tg of about 44° C., obtained from the inflection point of the reversing heat flow trace, using a temperature ramp of 1° C./min or (iii) the characteristics of (i) and (ii).

### Claim 14 (depends on 13)

The amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol of claim 13 having (i) a thermogravimetric analysis thermogram weight loss of about 11% when heated from about 30° C. to about 110° C. and an additional weight loss of about 5% when heated further to 200° C., obtained using a temperature ramp of 10° C./min, (ii) a Raman spectrum with absorptions at peak positions of about 2105 and 1673 cm−1; optionally with one, two or three peak positions selected from the group consisting of 2972, 2937, 684, 538, 484, 470, 372 and 226 cm−1 or a Raman spectrum substantially identical to that of FIG. 19A or FIG. 19B, or (iii) the characteristics of (i) and (ii).

### Claim 15

A method to make crystalline Form I 17α-ethynyl-androst-5-ene-3β,7β,17β-triol comprising the step of reducing in volume a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in methanol-water, methanol-tetrahydrofuran or acetone or removing methanol from a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in methanol-water by distillation concommitant with addition of water wherein the initial volume of the solution is substantially maintained or removing solvent from a solution of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol in ethanol by evaporation.

### Claim 16

A method to treat an inflammation condition or a metabolic disorder in a subject comprising administering to the subject an effective amount of crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol, optionally wherein the crystalline 17α-ethynylandrost-5-ene-3β,7β,17β-triol is Form I 17α-ethynylandrost-5-ene-3β,7β,17β-triol substantially free of amorphous 17α-ethynylandrost-5-ene-3β,7β,17β-triol or other crystalline forms of 17α-ethynylandrost-5-ene-3β,7β,17β-triol.

### Claim 17 (depends on 16)

The method of claim 16 wherein the metabolic disorder is type 2 diabetes, hyperglycemia, obesity or hypercholesterolemia.

### Claim 18 (depends on 16)

The method of claim 16 wherein the inflammation condition is Alzheimer's Disease, Parkinson's Disease, inflammation associated with ischemia, hemorrhage or a trauma, optionally a myocardial infarction or a stroke, an autoimmune disease, optionally type 1 diabetes, multiple sclerosis, rheumatoid arthritis or an inflammatory bowel disease, optionally ulcerative colitis or Crohn's Disease.
